Top in ID: Intranasal COVID-19 vaccine shows promise; MRSA contact precautions questioned
An intranasal COVID-19 vaccine candidate, CoviLiv, induced a robust immune response, according to a presentation at IDWeek. Researchers plan to test multiple dose levels and observe participants for 2 months after its administration.
“Live-attenuated virus vaccines are a modality that have been around for decades. The trial that [these data are] from is a first in-human clinical trial that was a placebo-controlled dose escalation trial using CoviLiv that is delivered intranasally,” Johanna K. Kaufmann, PhD, executive vice president of oncology and immunology at Codagenix Inc., said during an IDWeek press conference.
It was the top story in infectious disease last week.
Another top story was a Q&A with Daniel J. Diekema, MD, D(ABMM), professor at the University of Iowa Carver College of Medicine and vice chair of research at the Maine Medical Center’s department of medicine, about a paper he wrote questioning MRSA prevention recommendations. In his paper, Diekema argues that there are not enough data to justify broad use contact precautions for patients in acute-care facilities who are known to be infected.
Read these and more top stories in infectious disease below:
Intranasal COVID-19 vaccine candidate generates robust immune response
Two doses of an experimental live-attenuated intranasal COVID-19 vaccine generated a robust immune response, according to phase 1 data presented at IDWeek. Read more.
Q&A: Are contact precautions essential for MRSA prevention?
Updated recommendations for MRSA prevention in acute-care facilities suggest contact precautions for patients known to be infected are “essential,” although researchers argue that the data do not justify the recommendation. Read more.
Cancer center’s anti-COVID efforts reduced nosocomial infections
Enhanced infection prevention and control efforts during COVID-19 reduced the rates of some hospital infections at a comprehensive cancer center, including Clostridioides difficile and multidrug-resistant infections, according to a study. Read more.
Wastewater signals match spikes in clinical cases of COVID-19, flu, RSV
Expanded use of wastewater surveillance confirmed spikes in clinical cases of COVID-19, influenza and respiratory syncytial virus in one of Canada’s largest cities, according to study findings presented at IDWeek. Read more.
IDWeek returns with relaxed COVID-19 policies
IDWeek relaxed its COVID-19 policies this year, no longer requiring that attendees wear a mask or provide proof of vaccination. Read more.